Alterations of blood-brain barrier and associated factors in acute liver failure
This article briefly outlines the efficacy and safety data of the drug treatment pipeline for obesity, with a focus on incretin-based medications, and discusses the clinical challenges and significance brought about by this new era
FREE consultations and flexible financing available
p = 0.009), 46% with 800 mg (95% CI: 33-60
Cuthbertson DJ, Irwin A, Gardner CJ et al (2012) Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists
Tracking waist circumference, body measurements, and how clothes fit can provide a more complete picture of progress